Key Points
- CAO Jennifer Mak sold 894 shares on Dec. 4 at an average price of $550 for total proceeds of $491,700, trimming her stake by 6.20% to 13,514 shares valued at $7,432,700.
- Axon missed EPS in the latest quarter (EPS $1.17 vs. $1.63 estimate) while revenue grew 30.6% year‑over‑year to $710.64 million.
- The stock trades at a high valuation (market cap ~$43.65B, P/E ~175) with ~79% institutional ownership and a consensus analyst rating of “Moderate Buy” and an average price target of $815.
Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) Director Jeri Williams sold 100 shares of the company's stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $550.63, for a total transaction of $55,063.00. Following the completion of the sale, the director directly owned 1,316 shares of the company's stock, valued at $724,629.08. The trade was a 7.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Jeri Williams also recently made the following trade(s):
- On Thursday, September 11th, Jeri Williams sold 100 shares of Axon Enterprise stock. The stock was sold at an average price of $752.54, for a total value of $75,254.00.
Axon Enterprise Stock Performance
Shares of AXON stock opened at $553.12 on Tuesday. The stock's 50-day moving average price is $636.04 and its 200 day moving average price is $718.82. The company has a quick ratio of 2.89, a current ratio of 3.12 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $43.65 billion, a PE ratio of 175.04, a price-to-earnings-growth ratio of 126.54 and a beta of 1.40. Axon Enterprise, Inc has a 52-week low of $469.24 and a 52-week high of $885.91.
Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share for the quarter, missing analysts' consensus estimates of $1.63 by ($0.46). Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The company had revenue of $710.64 million for the quarter, compared to analyst estimates of $704.83 million. During the same period in the previous year, the business posted $1.45 earnings per share. The firm's revenue was up 30.6% compared to the same quarter last year. As a group, equities research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.
Wall Street Analyst Weigh In
AXON has been the topic of a number of analyst reports. Weiss Ratings reiterated a "hold (c-)" rating on shares of Axon Enterprise in a research report on Monday, December 1st. UBS Group reduced their target price on shares of Axon Enterprise from $840.00 to $610.00 and set a "neutral" rating for the company in a research note on Wednesday, November 5th. Wall Street Zen lowered shares of Axon Enterprise from a "hold" rating to a "sell" rating in a research note on Saturday, November 8th. Piper Sandler cut their price target on shares of Axon Enterprise from $893.00 to $753.00 and set an "overweight" rating for the company in a report on Wednesday, November 5th. Finally, Royal Bank Of Canada began coverage on shares of Axon Enterprise in a research report on Monday, November 17th. They issued an "outperform" rating and a $860.00 price objective for the company. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $815.00.
Check Out Our Latest Report on AXON
Hedge Funds Weigh In On Axon Enterprise
Large investors have recently made changes to their positions in the stock. Stone House Investment Management LLC purchased a new position in Axon Enterprise in the 3rd quarter valued at approximately $29,000. New Millennium Group LLC acquired a new stake in Axon Enterprise in the third quarter valued at $29,000. Banque Transatlantique SA purchased a new position in shares of Axon Enterprise in the first quarter valued at $31,000. Flaharty Asset Management LLC purchased a new position in shares of Axon Enterprise in the first quarter valued at $33,000. Finally, Hemington Wealth Management raised its stake in shares of Axon Enterprise by 70.8% during the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company's stock worth $33,000 after buying an additional 17 shares during the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.
About Axon Enterprise
(
Get Free Report)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
